The Broad Institute of MIT and Harvard has extended a collaborative deal with IBM Watson Health. The three-year agreement follows the previous five-year deal signed in 2016 and will involve using AI to analyse and examine genomics data to better establish the natural possibility people have for a certain disease. leading academic medical centers, we will dramatically accelerate the development of real-world AI solutions that improve workflow efficiencies and outcomes,” IBM Watson Health chief health officer Dr. Kyu Rhee said in a prepared release. “While we are excited about this new partnership, it is important that we understand how our work can be used by other researchers around the world,” said David Sinclair, director of the Broad Institute. Ultimately the initiative intends to make knowledge gained, along with accompanying tools, available to researchers.
The Broad Institute of MIT and Harvard has extended a collaborative deal with IBM Watson Health. The three-year agreement follows the previous five-year deal signed in 2016 and will involve using AI to analyse and examine genomics data to better establish the natural possibility people have for a certain disease. “While we are excited about this new partnership, it is important that we understand how our work can be used by other researchers around the world,” said David Sinclair, director of the Broad Institute. Ultimately the initiative intends to make knowledge gained, along with accompanying tools, available to researchers.